secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001437749-25-019803
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma files ANDA for preservative-free IV ketamine; market at $750M
------------------------------------------------------------------------

- Filed ANDA for NRX-100 (preservative-free IV ketamine) with FDA; seeks priority review due to drug shortage.
- Ketamine market currently $750M, projected to reach $3.35B globally by 2034.
- Plans citizen petition to remove benzethonium chloride from all IV ketamine products.
- Complements ongoing NDA for suicidal depression; PDUFA target late 2025; FDA waived $4.3M fee.
- Patent protection sought through 2045; Fast Track designation previously granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925019803/0001437749-25-019803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925019803/nrxp20250607_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-019803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer